CY1108474T1 - Ανοσοθεραπευτικοι συνδυασμοι για την αγωγη των ογκων - Google Patents

Ανοσοθεραπευτικοι συνδυασμοι για την αγωγη των ογκων

Info

Publication number
CY1108474T1
CY1108474T1 CY20081101242T CY081101242T CY1108474T1 CY 1108474 T1 CY1108474 T1 CY 1108474T1 CY 20081101242 T CY20081101242 T CY 20081101242T CY 081101242 T CY081101242 T CY 081101242T CY 1108474 T1 CY1108474 T1 CY 1108474T1
Authority
CY
Cyprus
Prior art keywords
receptors
immunotherapeutic
treatment
ligands
patients
Prior art date
Application number
CY20081101242T
Other languages
English (en)
Inventor
Rodriguez Rolando Perez
Marinello Gisela Maria Gonzalez
Ramos Tania Crombet
Delgado Irene Beausoleil
Cuba
Original Assignee
Centro De Inmunologia Molecular
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centro De Inmunologia Molecular filed Critical Centro De Inmunologia Molecular
Publication of CY1108474T1 publication Critical patent/CY1108474T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001104—Epidermal growth factor receptors [EGFR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00113—Growth factors
    • A61K39/001131—Epidermal growth factor [EGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00113—Growth factors
    • A61K39/001134—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Η εφεύρεση σχετίζεται με το πεδίο της ανοσολογίας, περισσότερο δε ειδικότερα με την ανοσοθεραπεία του καρκίνου, ειδικότερα δε με την χρήση ανοσοθεραπευτικών συνδυασμών και με μεθόδους αγωγής για την πρόληψη της ανάπτυξης των κυττάρων των όγκων και/ή την απαλοιφή των εν λόγω κυττάρων. Οι μέθοδοι που αποκαλύπτονται και δημοσιοποιούνται ως αναφορά σύμφωνα με την εφεύρεση βασίζονται στην αναστολή των υποδοχέων πρωτεϊνών κινάσης σε κατάλοιπα τυροσίνης (RTK) και με τους προσδέτες για τους εν λόγω υποδοχείς. Η εφεύρεση περιγράφει ανοσοθεραπευτικούς συνδυασμούς οι οποίοι αναστέλλουν τους υποδοχείς RTK και/ή τους προσδέτες αυτών μέσω συνδυασμού ενεργής και/ή παθητικής ανοσοθεραπείας έναντι των εν λόγω υποδοχέων. Οι μέθοδοι που αποκαλύπτονται και δημοσιοποιούνται ως αναφορά μπορούν να χρησιμοποιηθούν σε ασθενείς με διαφορετικές κλινικές καταστάσεις όγκων επιθηλιακής προέλευσης οι οποίες υπερ-εκφράζουν τους εν λόγω υποδοχείς. Ο ενεργός και παθητικός ανοσοθεραπευτικός συνδυασμός μπορεί να χρησιμοποιηθεί ταυτόχρονα ή επαγωγικά εξαρτώμενου του εάν η θεραπευτική μέθοδος πρόκειται να χρησιμοποιηθεί σε ασθενείς με μία προχωρημένη κατάσταση πάθησης ή ως ανοσοενισχυτική θεραπεία.
CY20081101242T 2000-12-08 2008-11-03 Ανοσοθεραπευτικοι συνδυασμοι για την αγωγη των ογκων CY1108474T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CU20000287A CU22979A1 (es) 2000-12-08 2000-12-08 Combinación inmunoterapéutica para el tratamiento de tumores que sobre-expresan receptores con actividad quinasa en residuos de tirosina
EP01999388A EP1350521B1 (en) 2000-12-08 2001-12-06 Immunotherapeutic combinations for the treatment of tumors

Publications (1)

Publication Number Publication Date
CY1108474T1 true CY1108474T1 (el) 2014-04-09

Family

ID=40261022

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20081101242T CY1108474T1 (el) 2000-12-08 2008-11-03 Ανοσοθεραπευτικοι συνδυασμοι για την αγωγη των ογκων

Country Status (26)

Country Link
US (2) US20020160014A1 (el)
EP (2) EP2005996A3 (el)
JP (2) JP2005519023A (el)
KR (1) KR20030064416A (el)
CN (1) CN1326566C (el)
AR (1) AR031641A1 (el)
AT (1) ATE403438T1 (el)
AU (2) AU2152102A (el)
BR (1) BR0116010A (el)
CA (1) CA2431199C (el)
CU (1) CU22979A1 (el)
CY (1) CY1108474T1 (el)
DE (1) DE60135248D1 (el)
DK (1) DK1350521T3 (el)
EA (1) EA007381B1 (el)
ES (1) ES2311036T3 (el)
HK (1) HK1073244A1 (el)
MX (1) MXPA03005030A (el)
MY (1) MY138833A (el)
NZ (1) NZ526284A (el)
PE (1) PE20020695A1 (el)
PT (1) PT1350521E (el)
SI (1) SI1350521T1 (el)
UY (1) UY27058A1 (el)
WO (1) WO2002045747A1 (el)
ZA (1) ZA200304415B (el)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7507724B2 (en) * 2001-01-16 2009-03-24 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
EP1493445A1 (en) * 2003-07-04 2005-01-05 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibition of stress-induced ligand-dependent EGFR activation
CU23297A1 (es) * 2004-11-16 2008-07-24 Ct De Inmunologa A Molecular Formulaciones inmunoterapã0/00uticas para la inducciã"n de autoanticuerpos bloqueadores de la uniã"n de interleucina-2 a su receptor. su uso en el tratamiento del cã ncer
US8323644B2 (en) * 2006-01-17 2012-12-04 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
US20090053221A1 (en) * 2006-01-17 2009-02-26 Cheung Nai-Kong V Immune response enhancing glucan
MX2009003738A (es) * 2006-10-12 2009-07-17 Forerunner Pharma Res Co Ltd Diagnóstico y tratamiento de cáncer usando anticuerpo anti-ereg.
CU23652A1 (es) * 2007-06-29 2011-05-27 Centro Inmunologia Molecular Composición vacunal homogénea para el tratamiento del cáncer y su método de obtención
KR101290503B1 (ko) 2008-01-17 2013-07-26 아이알엠 엘엘씨 개선된 항-ｔｒｋｂ 항체
JP5808052B2 (ja) 2009-05-29 2015-11-10 中外製薬株式会社 Ｅｇｆファミリーリガンドのアンタゴニストを成分とする医薬組成物
WO2012018260A1 (en) * 2010-08-05 2012-02-09 Universiteit Utrecht Holding B.V. Epidermal growth factor receptor targeted immune therapy
TWI593705B (zh) 2011-12-28 2017-08-01 Chugai Pharmaceutical Co Ltd Humanized anti-epiregulin antibody and cancer therapeutic agent containing the antibody as an active ingredient
EP3583113A4 (en) * 2017-02-17 2020-08-26 George Todaro USE OF TGF-ALPHA FOR TREATMENT OF DISEASES AND DISORDERS

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22545A1 (es) * 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
JPH01221326A (ja) * 1988-02-29 1989-09-04 Toyo Jozo Co Ltd 悪性腫瘍細胞障害剤
US5705157A (en) * 1989-07-27 1998-01-06 The Trustees Of The University Of Pennsylvania Methods of treating cancerous cells with anti-receptor antibodies
EP0586002B1 (en) * 1992-08-18 2000-01-19 CENTRO de IMMUNOLOGIA MOLECULAR Monoclonal antibodies recognizing the epidermal growth factor receptor, cells and methods for their production and compositions containing them
CA2137639C (en) * 1993-12-09 1999-01-26 Agustin B. L. Davila Vaccine composition comprising autologous epidermal growth factor or a fragment or a derivate thereof having anti-tumor activity and use thereof in the therapy of malignant diseases
CA2261433A1 (en) * 1993-12-09 1995-06-10 Belinda Sanchez Ramirez Composition comprising autologous epidermal growth factor
CU22615A1 (es) * 1994-06-30 2000-02-10 Centro Inmunologia Molecular Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos
DE69827621T9 (de) * 1997-05-12 2007-06-06 Aphton Corp., Woodland Immunogene zusammensetzungen gegen den cck-b-gastrin-rezeptor und verfahren zur behandlung von tumoren
US20030219380A1 (en) * 1997-11-07 2003-11-27 Annie Fong Method of determining an efficacious dose of a drug
EP1075184A4 (en) * 1998-05-08 2002-01-30 Sloan Kettering Inst Cancer ACTIVE VACCINATION COMPOSITIONS AND METHODS
KR20010071271A (ko) * 1998-05-15 2001-07-28 존 비. 랜디스 방사선 및 성장 인자 수용체 티로신 키나아제 억제제에의한 사람 종양의 치료법
US6498181B1 (en) * 1999-01-06 2002-12-24 Maxim Pharmaceuticals Synergistic tumorcidal response induced by histamine
AU2001259452A1 (en) * 2000-05-05 2001-11-20 Aphton Corporation Chimeric peptide immunogens their preparation and use
CU23077A1 (es) * 2000-12-06 2005-08-17 Centro Inmunologia Molecular Composicion vacunal que contiene factor de crecimiento transformante (tgf-alfa). su uso en la terapia de enfermedades malignas

Also Published As

Publication number Publication date
CU22979A1 (es) 2004-09-09
ATE403438T1 (de) 2008-08-15
MY138833A (en) 2009-07-31
DE60135248D1 (de) 2008-09-18
AU2152102A (en) 2002-06-18
NZ526284A (en) 2004-11-26
CN1326566C (zh) 2007-07-18
ES2311036T3 (es) 2009-02-01
EP2005996A3 (en) 2012-01-25
US20020160014A1 (en) 2002-10-31
CA2431199C (en) 2011-10-04
JP2005519023A (ja) 2005-06-30
KR20030064416A (ko) 2003-07-31
UY27058A1 (es) 2002-03-22
SI1350521T1 (sl) 2008-12-31
JP2010150286A (ja) 2010-07-08
US20060188497A1 (en) 2006-08-24
EA007381B1 (ru) 2006-10-27
HK1073244A1 (en) 2005-09-30
DK1350521T3 (da) 2008-11-10
AR031641A1 (es) 2003-09-24
EP1350521B1 (en) 2008-08-06
EA200300646A1 (ru) 2003-10-30
CA2431199A1 (en) 2002-06-13
PE20020695A1 (es) 2002-09-23
MXPA03005030A (es) 2004-09-10
PT1350521E (pt) 2008-11-14
CN1592636A (zh) 2005-03-09
WO2002045747A1 (es) 2002-06-13
AU2002221521B2 (en) 2007-01-04
ZA200304415B (en) 2004-07-07
EP2005996A2 (en) 2008-12-24
US7744871B2 (en) 2010-06-29
BR0116010A (pt) 2004-01-06
EP1350521A1 (en) 2003-10-08

Similar Documents

Publication Publication Date Title
CY1108474T1 (el) Ανοσοθεραπευτικοι συνδυασμοι για την αγωγη των ογκων
CY1123535T1 (el) Υποκαταστατο θεραπευτικο τελικο σημειο για βασιζομενη σε anti-ctla-4 ανοσοθεραπεια ασθενειας
CY1120070T1 (el) Μεθοδοi θεραπευτικης αγωγης με τη χρηση συζευγματων αντισωματος εναντι-erbb-μεϋτανσινοειδους
CY1113260T1 (el) ΘΕΡΑΠΕΥΤΙΚΗ ΑΓΩΓΗ ΚΑΡΚΙΝΟΥ ME TO ANTI-ErbB2 ΑΝΑΣΥΝΔΥΑΣΜΕΝΟ ΑΝΘΡΩΠΟΠΟΙΗΜΕΝΟ ΜΟΝΟΚΛΩΝΙΚΟ ΑΝΤΙΣΩΜΑ 2C4 (rhuMab 2C4)
WO2005062972A3 (en) Treatment of cancer with novel anti-il 13 monoclonal antibodies
WO2008077077A3 (en) Vegf-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors
NO331072B1 (no) Sammensetning som omfatter et angiogenese inhiberende middel og et anti tumor-immunoterapeutisk middel samt anvendelser av det samme.
CY1110256T1 (el) Διαμεμβρανικο αντιγονο λεκτινης τυπου c εκφραζομενο σε καρκινο στον προστατη ανθρωπου και χρησεις αυτου
CY1108765T1 (el) ΑΓΩΓΗ ME ΑΝΤΙΣΩΜΑΤΑ ANTI-ErbB2
CY1109421T1 (el) ΔΟΣΕΙΣ ΓΙΑ ΑΓΩΓΗ ΜΕ ΑΝΤΙΣΩΜΑΤΑ ΑΝΤΙ-ErbB2
BRPI0509177A (pt) uso de anticorpos anti-alfa5beta1 para inibir a proliferação de células cancerìgenas
CY1110874T1 (el) Μεθοδοι θεραπειας για συμπαγεις ογκους που εκφραζουν to cd40 αντιγονο κυτταρικης επιφανειας
CY1115407T1 (el) Θοριο-227 για χρηση στην ακτινοθεραπεια ασθενειων των μαλακων ιστων
EA201071422A1 (ru) Способы лечения заболеваний, связанных с мейотическим кинезином
ATE419516T1 (de) Monoklonale antikörper und zelloberflächenantigene zum nachweis und zur behandlung von kleinzelligem lungenkrebs (sclc)
DK0939809T3 (da) TIE-2 receptor-ligand (TIE ligand-4) og dens anvendelse
CY1111522T1 (el) 84p2a9: ειδικη σε προστατη και ορχεις πρωτεϊνη που εκφραζεται σε υψηλο βαθμο στον προστατικο καρκινο
CY1109029T1 (el) Νουκλεϊνικο οξυ και αντιστοιχη πρωτεϊνη ονομαζομενη 85p1b3 χρησιμα στην αγωγη και τον εντοπισμο του καρκινου
DE69927286D1 (de) Verwendung von humanen prostatazellinien zur behandlung von prostatakrebs
DE60123138D1 (de) Verwendung von progesteronrezeptorhemmern zur behandlung von steroid-resistentem brustkrebs
EA200701071A1 (ru) Иммунотерапевтические композиции для получения аутоантител, способных предотвращать связывание интерлейкина-2 со своим рецептором и их использование в лечении рака
DE60212415D1 (de) Die verwendung von einer 4-pyridylmethylphtalazine enthaltenden kombination zur behandlung von tumoren
Agaugue et al. The high expression of NKG2D ligands on tumor and the lack of surface expression on healthy tissues provides a strong rationale to support NKG2D-based therapeutic approaches for cancer
小野博史 et al. The Drug Uptake in the Tumor When the Mild-Hyperthermia Treatment in Combination with the Chemotherapy in vivo.
Gan et al. Humanized knock-in mouse models for evaluating in vivo efficacy of immune-oncology drugs targeting stimulatory immune checkpoint molecules